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Abstract  
The aim of this study was to investigate the relationship between cardiopulmonary exercise testing 
(CPET) and the presence of obstructive sleep apnea syndrome (OSAS) in order to provide an 
innovative tool to identify patients with OSAS. A prospective nested case control design was 
adopted. A consecutive population of male volunteers referred to a Sleep Unit was subjected to 
nocturnal polysomnography, full lung function testing and maximal CPET. A stepwise linear 
discriminant function analysis (DFA) was applied to construct a model which could identify 
individuals with moderate-to-severe OSAS from healthy controls. The total of 30 volunteers formed 
the OSAS and 24 the non-OSAS groups. Demographic and somatometric parameters were similar 
between groups. Patients presented with lower Expiratory Reserve Volume (ERV: 106.7±28.3 vs. 
123.9±22.1, p<0.001), Leg FatigueBorg scale (3.9±1.1 vs. 6.1±1.4, p<0.001), VO2peak(25.0±5.9 vs. 32.9±7.2 
ml/kg-1/min-1, p<0.001), peak breathing frequency (31.0±5.8 vs. 35.5±7.3 1/min-1, p<0.001) and peak 
heart rate (151.1±17.7 vs. 171.2±12.6 beats/min-1, p<0.001) compared to controls, but higher peak 
end-tidal CO2 (PETCO2peak:38.6±4.2 vs. 35.0±4.9 mmHg, p=0.043) and peak systolic (SBP:188.3±21.9 vs. 
173.1±17.9 mmHg, p=0.009) and diastolic (DBP: 91.3±8.2 vs. 85.4±8.2 mmHg, p=0.011) blood 
pressure. Stepwise DFA indicated that ERV% of predicted (0.372), PETCO2peak (-0.376), SpO2resting (0.0667), 
Leg Fatigue Borg scale (0.564), HRpeak (0.530) and DBPpeak (-0.543) could separate the two groups, with an 
overall predictive accuracy of 96.3%. Selected CPET parameters (ERV% of predicted, PETCO2peak, SpO2resting, 
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HRpeak, DBPpeak and Leg FatigueBorg Scale) are independently associated with OSAS presence and could 
discriminate patients with and without this disorder. 
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Abbreviations  
AHI = apnea-hypopnea index; BMI = body mass index; CPET = cardio-pulmonary exercise testing; DBP 
= diastolic blood pressure; DI = oxygen desaturation index during sleep; ERV = expiratory reserve 
volume; ESS = Epworth Sleepiness Scale; FEV1 = forced expiratory volume in 1
st s; FVC = forced vital 
capacity; fβ = breath frequency; HR = heart rate; MinSaO2 = minimum oxygen saturation during sleep; 
MVV = maximum voluntary volume; O2pulse = ratio between oxygen uptake and heart rate; OSAS = 
obstructive sleep apnea syndrome; PEF = peak expiratory force; PETCO2 = end-tidal carbon dioxide 
pressure; PETO2 = end-tidal oxygen pressure; RER = respiratory exchange ratio; SBP = systolic blood 
pressure; SpO2 = blood oxygen saturation with pulse oximetry; VCO2 = carbon dioxide output; VE = 
minute ventilation; VO2 = oxygen uptake 
 
Introduction  
Obstructive sleep apnea syndrome (OSAS) is a common condition affecting 5-to-10% of the 
general population (Punjabi, 2008). It is characterized by recurrent upper airway collapse during 
sleep resulting in frequent arousals and sleep fragmentation. The pathophysiological consequences 
of the syndrome are several, including intermittent nocturnal hypoxia, large negative inspiratory 
deflection of intrathoracic pressure, hypercapnia, and increased systemic inflammation (Chiang et al., 
2006). 
Cardiopulmonary exercise testing (CPET) is a non-invasive technique which provides an 
objective quantitative assessment of metabolic, pulmonary and cardiovascular responses during 
exercise (Boutou et al., 2014). Available data indicate that CPET could be utilised to stratify the 
cardiovascular risk among patients with OSAS (Mansukhani et al., 2013), in a similar manner to 
coronary artery disease patients. Patients with OSAS have reduced VO2peak, while they present with 
chronotropic incompetence and abnormal exercise blood pressure responses (Aron et al., 2009). Left 
heart disease (Lin et al., 2006), chronic sympathetic over-activation and endothelial dysfunction 
(Aron et al., 2009) are potential explanations, along with impaired muscle metabolism, possibly due 
to long-term exposure to conditions of hypoxia (Bonanni et al., 2004).  
The aim of this study was to investigate whether the parameters of CPET can identify the 
presence of obstructive sleep apnea syndrome, and identify independent predictors in a cohort of 
patients evaluated for sleep disordered breathing in order to provide a supplemental tool to identify 
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patients with OSAS. We hypothesized that the patients with OSAS present a distinct cardiopulmonary 
pattern during exercise and the apnea-hypopnea index (AHI) could differentiate the patients with 
(AHI >15 events/h-1) and without (AHI <5 events/h-1) OSAS. 
Methods 
Study population 
All males who were consecutively referred to the Sleep Units (University Hospital, Larissa, 
Greece) for suspected OSAS (Figure 1) between July 2017 and June 2018 (Table 1) constituted the 
initial study cohort. Inclusion criteria were age between 30-to-60 years and BMI<40 kg/m2. Exclusion 
criteria were BMI≥40 kg/m2, diabetes mellitus, heart failure, chronic obstructive pulmonary disease 
and/or other respiratory illness, peripheral vascular disease (that would limit exercise capacity), 
myocardial infarction within the previous month, severe uncontrolled arrhythmia and medicated 
arrhythmia, severe and uncontrolled hypertension, severe aortic stenosis, renal failure, anemia, 
mental illness and any form of musculoskeletal disability which could impair maximum exercise 
capacity. The study was approved by the Institutional Ethics Committee and informed consents were 
obtained from all participants (No. of Ethical Committee: 21/09-01-2017, University of Thessaly). 
Insert Figure 1 here 
Study protocol 
Α prospective nested case-control study was performed. Baseline and two other visits were 
piloted. During baseline visit detailed medical history, anthropometric data, physical examination 
and Epworth Sleep Scale (ESS), (Johns, 1991) were recorded. During the first visit all participants 
underwent night polysomnography (PSG) and subsequently subjects who were diagnosed with OSAS 
constituted the patients΄group, while subjects without OSAS or other forms of sleep-disordered 
breathing, constituted the control group. 
During the second visit (within 48-hours from the first one) all participants were subjected to 
Doppler echocardiography (for exclusion of heart failure and/or severe valvular disorder) (Zamorano 
et al., 2011), lung function measurements (Miller et al., 2005) and performed maximal CPET 
(Wasserman et al., 2004). 
Polysomnography 
PSG included electroencephalography, electrooculography, submental electromyography, 
anteriortibialis electromyography, nasal cannula airflow signal using a nasal cannula/pressure 
transducer system, oral thermistor, electrocardiography, and body position. Sleep was scored 
manually according to the criteria of Rechtschaffen and Kales (1968). Respiratory efforts were 
monitored with abdominal and thoracic bands. Arterial SaO2 was measured using SpO2. Apnea was 
defined as complete cessation of airflow for at least 10s in duration. Hypopnea was defined as one of 
the following three: 1) >50% reduction in airflow, 2) <50% reduction in airflow associated with a 
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desaturation of>3%, or 3) a moderate reduction in airflow with associated arousal by 
electroencephalography. Apneas were classified as obstructive, central, or mixed according to the 
presence or absence of respiratory efforts. Patients with predominant obstructive sleep apneas and 
AHI≥5/h-1 were diagnosed with the OSAS. 
Spirometry and lung volumes measurements  
All participants underwent standard spirometry and lung volume measurements, in line with 
ATS/ERS guidelines (Miller et al., 2005). Maximal flow-volume loops were conducted for each subject 
with sitting position using MasterScreen-CPX pneumotachograph (VIASYS HealthCare, Germany). For 
each pulmonary function test, three maximal flow-volume loops were obtained to determine FVC 
and FEV1; the largest one was retained to calculate the ratio of FEV1 to FVC (FEV1/FVC). Thoracic gas 
volume at FRC level, ERV, inspiratory capacity (IC) and vital capacity (VC) were measured, while 
subjects made gentle pants against the shutter at a rate of <1/s. The mean of three technically 
acceptable FRC measurements was used to calculate total lung capacity (TLC) as FRC+IC and residual 
volume as TLC-VC.  
Maximum CPET 
An electronic cycle ergometer (Ergoselect 100, Germany) MasterScreen-CPX was used for all 
respiratory and cardiac parameters (VIASYS HealthCare, Germany). Prior to testing all participants 
were familiarized with the cycle ergometer via a 2 min resting; for a 3 min unloaded cycling which 
also served as warm-up; after the end of the maximal test they performed a 5 min unloaded cycling 
for recovery purposes. The work rate increment calculated using the Wasserman et al. (2004) 
formula: 
Work Rate/min-1(ramp) = (VO2peak-VO2unloaded) / 100  
VO2peak = (Height(cm) - Age(yrs)) x 20; VO2unloaded = 150 + (6 x Weight(kg)) 
During testing, patients were instructed to keep a steady speed of 60-65 rpm throughout 
both the unloaded and exercising phase. Each trial was terminated when the participant reached 
symptom-limited maximum exercise, which was confirmed by the presence of RER >1.10, HR≥80% of 
predicted HRmax, and/or plateau of oxygen consumption with increasing work load (ATS/ACCP, 2003). 
A 12-lead ECG was also employed for HR monitoring, while SpO2 was continuously measured using 
(MasterScreen, Germany). Blood pressure was recorded at rest and every 2-min during exercise and 
recovery phases using manual cuff manometry (Mac, Japan). 
Statistical analyses 
Univariate Analyses 
All analyses were conducted using SPSS 19.0 (IBM Corporation, San Diego, CA). The 
Kolmogorov-Smirnov test was utilized to assess data normality. Univariate group comparisons were 
conducted using either the Independent Samples Student’s T-test, for continuous variables or the 
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Chi-square test for qualitative variables. A level of p value <0.05 was considered statistically 
significant for all analyses.  
Multivariate Analyses 
The stepwise linear discriminant (LD) model was applied to our data, in order to produce a 
LD function. By definition, this resulting function may be subsequently used to classify new cases. 
The discriminant formula for a population of [1, 2..., n] subjects, with [1, 2..., i] canonical 
standardized discriminant function coefficients is described below, 
Dj=k1mn1+k2mn2...+kimni 
where: “j” is the number of discriminant functions extracted, with jЄ[1, c-1];  “Dj” is the discriminant 
function score for the jth discriminant function; “ki” is the canonical standardized discriminant 
function coefficient; “mni” is the predictor variable value for the ith subject and the nth discriminant 
function coefficients. The interpretation of the D score was performed using each group’s centroids. 
Since the groups were two, the cut score was calculated half-way the 2 centroids as: Cut score = 
(group 1 centroid-group 2 centroid) / 2. The Wilk’s lambda test was used to determine the derived 
DFA model’s goodness of fit. A 2x2 confusion matrix was furthermore used to determine the 
function’s predictive accuracy, whereas the cross-validated predictive accuracy was estimated via the 
“leave-one-out” classification process (Burns & Burns, 2009). The statistical significance was set at p 
<0.05. 
Results 
Out of the 245 individuals who were assessed for eligibility, 54 were selected; 30 patients with OSAS 
and 24 controls (Figure 1). Univariate group comparison regarding demographic and anthropometric 
characteristics, lung function measurements and polysomnography variables are presented in Table 
1.  
 
Insert Table 1 here 
 
Univariate group comparison regarding CPET parameters is presented in Table 2. During 
unloaded pedaling, OSAS patients presented with lower VO2unloaded (3.5±0.9 vs. 4.6±1.6 ml/min
-1/kg-1; 
p=0.023), VCO2unloaded (2.7±0.8 vs. 3.3±1.2 ml/min
-1/kg-1; p=0.049), fβunloaded (12.8±1.8 vs. 14.7±4.1 
breaths/min-1; p=0.024) and SpO2unloaded (97.4±0.9 vs. 98.3±0.7 %; p<0.001) values and higher 
PETCO2unloaded (34.9±3.5 vs. 32.1±3.9 mmHg; p=0.006) values compared to controls. Further 
differences were noted between the groups at peak exercise. Patients with OSAS had lower VO2peak 
(25.0±5.9 vs. 32.9±7.2 ml/min-1/kg-1; p<0.001), VCO2peak (27.5±7.1 vs. 36.6±9.0 ml/min/kg; p<0.001), 
VEpeak (78.6±17.3 vs. 97.6±26.1 L/min; p=0.003), fβpeak (31.0±5.8 vs. 35.5±7.3 breaths/min
-1, p<0.001), 




1;p<0.000), while they revealed higher DBPpeak (91.3±8.2 vs. 85.4±8.2 mmHg; p=0.011), SBPpeak 
(188.3±21.9 vs. 173.1±17.9 mmHg; p=0.009) and PETCO2peak (38.6±4.2 vs. 35.0±4.9 mmHg; p=0.043), 
compared to the control group. However, leg fatigue was significantly more intense among controls 
compared to OSAS patients (6.1±1.4 vs. 3.9±1.1, p<0.001), although dyspnea severity was similar 
between the groups (Borg dyspnea 3.2±1.9 vs. 2.7±1.5, p=0.308). 
 
Insert Table 2 here 
 
Multivariate analysis was subsequently performed via the application of a linear DFA model 
for two groups (OSAS and non-OSAS group). Table 3 presents the canonical discriminant function 
coefficients used to create the discriminant model:  
D score(patients with and without OSAS) = 0.564 x Leg FatigueBorg Scale +0.530 x HRpeak +0.667 x SpO2resting -0.543 x 
DBPpeak +0.372 x ERV% of predicted -0.376 x PETCO2peak. 
 
Insert Table 3 here 
 
Centroid for the non-OSAS controls was 2.139 and -1.711 for the OSA patients, giving a cut-
score of 2.139-1.711 / 2 = 0.214. Therefore, a D score higher than 0.214 was associated with the 
absence of OSAS, while a D-score below than 0.214 was linked with the presence of OSAS. The 
overall predictive accuracy of the model in correctly classifying cases was 96.3%, with a sensitivity of 
95.8% and a sensitivity of 96.7%. 
Discussion 
The aim of this study was to investigate the whether exercise performance during maximum 
CPET could provide discriminative information which could facilitate the identification of OSAS 
presence in subjects with compatible symptomatology. Our main finding was that selected 
parameters obtained during CPET (i.e., ERV% of predicted, PETCO2peak, SpO2resting, Leg FatigueBorg Scale, HRpeak 
and DBPpeak) may serve as reliable predictors for OSAS.  
We found that patients with OSAS revealed significantly reduced actual ERV which is 
consistent with Hoffstein et al. (1984), who demonstrated that the cross sectional area of the 
pharyngeal airway decreases as lung volume decreases from FRC to residual volume suggesting the 
contribution of lung volumes (FRC or EELV) in the pathogenesis of OSAS. Appelberg et al. (2000) also 
found a significant correlation between ERV and both nocturnal apnoea and desaturation frequency, 
explained by the closure of peripheral airways especially in the lower dependent regions of the lung 
which may lead to an increased residual volume and to a decreased ERV. Further, Abdeyrim et al. 
(2015) demonstrated that FRC and ERV were decreased in pre-obese and obese patients with OSAS 
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independently from BMI and that OSAS had a negative impact on lung volume possibly due to the 
abnormally increased lung elasticity recoil pressure in OSAS patients. 
According to our data, patients with OSAS had higher unloaded PETCO2, lower unloaded SpO2, 
and lower unloaded breathing frequency, while at the peak of exercise they had higher PETCO2peak as 
well as lower fβpeak and VEpeak than the control group. OSAS is characterized by recurrent upper airway 
collapse during sleep which may cause CO2 retention and therefore respiratory acidosis, resulting in 
compensatory renal retention of bicarbonate ions and excretion of hydrogen ions. The upper airway 
is not obstructed when the patient is awake and thus arterial PCO2may then return to normal levels. 
The existing elevated bicarbonate levels may causeblunting of the respiratory center response, 
leading to decreased breathing frequency, and also metabolic alkalosis (Malley, 2005), resulting in 
compensatory respiratory acidosis through to reduced daily ventilation. Moreover, the blunted 
respiratory drive cannot compensate the increased respiratory load imposed during exercise, 
meaning that OSAS patients cannot eliminate the extra amount of CO2 produced during exercise 
(Hargens et al., 2009). Another explanation might be that due to the chronic blunting of the 
respiratory drive, the increase in breathing frequency is relatively low and therefore not enough for 
the elimination of the extra CO2 produced during exercise, resulting in the increased levels of PaCO2 
and PETCO2 (Dempsey, 2004). Furthermore, according to Bijaoui et al. (2002) lung resistance and 
elastance increase significantly during obstructed breathing, suggesting that OSAS may lead to 
transient abnormalities in the recruitment of lung units and the gas exchanging capacity of the lungs 
resulting in V/Q mismatching. The increased PETCO2 and the lower SpO2 levels, like the ones 
measured in our OSAS cohort, may, thus, be an end product of a complex conglomerate, influenced 
by factors such as severity of sleep apnea, daytime PaO2, blunted respiratory drive, respiratory 
mechanics and respiratory muscle fatigue (Kawata et al., 2007).  
Our results showed significantly lower difference in leg fatigue, and lower values in patients 
with OSAS, compared to controls (3.9±1.1 vs. 6.1±1.4). Leg muscle weakness and leg effort are 
different sensations, but they are recorded as a leg fatigue, and can limit maximum exercise during 
CPET (el-Manshawi et al., 1986). The intensity of leg effort is very subjective (Lin et al., 2006) and the 
average individual tolerates a greater degree of discomfort (very severe) compared to most patients, 
who tolerate only a little discomfort before stopping exercise (Chennaoui et al., 2015). Previous 
studies have demonstrated decreased maximum exercise capacity in OSA patients because of 
intolerance to exercise and susceptibility to leg fatigue (Aguillard et al., 1998). Since leg fatigue can 
reflect an impairment of muscle metabolism (Vanuxem et al., 1997) these symptoms are probably 
associated with decreased peripheral oxygen uptake among OSAS patients, with increased maximal 
lactate concentration and delayed lactate elimination of exercising muscles. The impairment in 
oxidative metabolism might be explained by the occurrence of mitochondrial abnormalities in 
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skeletal myofibres and could explain, in part, the increased production of reactive oxygen species 
exhibited in the neutrophils of OSAS patients (Bonanni et al., 2004). 
Previous reports have suggested altered hemodynamic response to exercise in OSAS (Malley, 
2005; Abdeyrim et al., 2015), while when OSAS is combined with obesity the hemodynamic response 
to exercise is further impaired (lower VO2peak, and lower HR response), as compared to simple obesity 
(Przybyłowski et al., 2007). In general, the present study supports these observations. The prevalence 
of chronotropic incompetence was much lower than reported by Grote et al. (2000). Moreover, in 
our study, age-adjusted HRpeak in severe OSAS was significantly lower compared with mild to 
moderate OSAS (91.2±9.7 vs. 94.3±10.9%), providing further evidence for blunted chronotropic 
response to graded exercise, which is consistent with other reports (Aguillard et al., 1998; Appelberg 
et al., 2000). The reasons for decreased chronotropic response to exercise in OSAS patients are not 
clear. It is suggested that the main causative factor is impaired cardiovascular autonomic function 
resulting from structural down regulation of cardiac β-receptors and/or altered baroreflex set-point 
(Somers et al., 1993). Increased SBPpeak and DBPpeak were also noted among OSAS patients, compared 
to controls a finding which might be related to sympathetic induced vasoconstriction, endothelial 
dysfunction, or a blunted response to beta-2 receptor stimulation, mechanisms that have been 
shown to be active in patients with sleep disordered breathing (Somers et al., 1993; Mansukhani et 
al., 2013).  
Limitations  
All data were prospectively collected and analyzed, so recall bias have been minimized. 
Moreover, all exercise tests were supervised and interpreted by the same team of ergophysiologists, 
thus minimizing diversities often encountered in studies with multicenter protocol. A limitations of 
this study might be the studied were all male and the lack of arterial blood gases measurements. 
PETCO2 has been used to indirectly estimate arterial CO2 pressure (PaCO2), in patients with lung 
disease. Nevertheless, the PETCO2 can differ from PaCO2 because of ventilation-perfusion (VA/Q) 
mismatching, and changes in PETCO2 may be seen with corresponding increase, decrease, or no 
change in PaCO2 depending on what happens to VA/Q mismatching (Abdeyrim et al., 2015). 
Nevertheless, the exclusion of patients with obstructive or other respiratory disorders has minimized 
this diversity. Furthermore, obtaining arterial blood gases during CPET demands the placement of a 
radial arterial catheter, an invasive technique which we wished to avoid, trying to minimize 
participants’ discomfort.  
Conclusions  
In this prospective, nested case-control study we identified that one lung function parameter 
(ERV% of predicted) and several CPET parameters (PETCO2peak, SpO2resting, Leg FatigueBorg Scale, HRpeak, and 
DBPpeak) are discriminative of the presence of OSAS with an accuracy of 96.3% in a subject population 
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with compatible symptomatology. Nocturnal PSG is certainly the gold standard for the diagnosis of 
OSAS and for its differential diagnosis of other forms of sleep disordered breathing. Although CPET 
cannot replace nocturnal PSG, it may be useful-when it is available-for initial evaluation of subjects 
with compatible symptomatology, in order to prioritize those where OSAS diagnosis is most likely. 
However, depending on the health insurance system of each country, it is an expensive examination 
which demands the hospitalization for at least one night and could be sometimes limited by the 
availability of beds and other resources. Larger, prospective studies are needed in order to further 
investigate whether CPET could have a supplemental role not only in the identification but also in the 
physical evaluation of subjects with sleep disordered breathing. 
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Figure 1. Study flow diagram.  
 
Table 1. Univariate analysis between demographic, respiratory and sleep apnea characteristics. 
Continuous variables are presented as mean ± standard deviation. 






Age, yrs 45.2 ± 10.0 41.0 ± 8.7 0.116 
BMI, kg/m2 31.3±4.3 29.7 ± 2.7 0.135 
FEV1, % 104.5 ± 22.1 109.5 ± 11.9 0.320 
FVC, % 106.1 ± 23.7 109.1 ± 14.1 0.586 
FEV1/FVC, % 80.9 ± 9.3 100.7 ± 6.1 0.282 
ERV, % 106.7 ± 28.3 123.9 ± 22.1 <0.001 
PEF, % 111.8 ± 14.1 103.3 ± 13.3 0.166 
AHI, events/h-1 44.9 ± 26.0 3.1± 0.8 <0.001 
Apnea, events/h-1 23.2 ± 24.2 1.7 ± 1.8 0.001 
Hypopnea, events/h-1 23.3±14.6 6.1±2.5 <0.001 
ESS 9.0±4.4 8.9±3.3 0.939 
DI, % 44.0±30.3 7.4±6.1 <0.001 
MinSaO2, % 78.5±10.7 89.6±3.2 <0.001 
Sleep Duration, min-1 316.4±55.2 299.8 ±50.2 0.261 
AHI = apnea-hypopnea index; BMI = body mass index; DI = desaturation index during sleep; ERV = expiratory 
reserve volume; ESS = Epworth Sleepiness Scale; FEV1 = forced expiratory volume in 1
st
s; FVC = forced vital 













Intensity of leg fatigue 3.9 ± 1.1 6.1 ± 1.4 <0.001 
Intensity of dysnea  3.2 ± 1.9 2.7 ± 1.5 0.308 
Watts, (J•s-1) 174.8±44.5 189.8±50.1 0.004 
VO2unloaded, ml/min
-1/kg-1 3.5 ± 0.9 4.6 ± 1.6 0.023 
VCO2unloaded, ml/min
-1/kg-1 2.7 ± 0.8 3.3 ± 1.2 0.049 
VEunloaded, L/min
-1 10.8 ± 2.5 10.8 ± 3.6 0.925 
Tidal Volumeunloaded, L 0.7 ± 0.2 0.8 ± 0.3 0.401 
fβunloaded,1/min
-1 12.8 ± 1.8 14.7 ± 4.1 0.024 
PETCO2unloaded, mmHg 34.9 ± 3.5 32.1 ± 3.9 0.006 
PETO2unloaded, mmHg 109.3 ± 5.7 108.6 ± 5.6 0.621 
SpO2unloaded,% 97.4 ± 0.9 98.3 ± 0.7 <0.001 
O2pulseunloaded, ml•min
-1/bpm-1 4.3 ± 1.2 4.09 ± 1.5 0.587 
SBPunloaded, mmHg 111.7 ± 7.3 112.7 ± 10.8 0.685 
DBPunloaded, mmHg 75.7 ± 7.5 76.2 ± 8.7 0.833 
    
VO2peak, ml/min
-1/kg-1 25.0 ± 5.9 32.9 ± 7.2 <0.001 
VCO2peak, ml/min
-1/kg-1 27.5 ± 7.1 36.6 ± 9.0 <0.001 
RER 1.10 ± 0.1 1.11 ± 0.8 0.494 
VEpeak, L/min
-1 78.6 ± 17.3 97.6 ± 26.1 0.003 
Tidal Volumepeak, L 2.5 ± 0.7 2.8 ± 0.8 0.259 
fβPeak, 1/min
-1 31.0 ± 5.8 35.5 ± 7.3 <0.001 
PETCO2peak, mmHg 38.6 ± 4.2 35.0 ± 4.9 0.043 
PETO2peak, mmHg 112.5 ± 4.6 116.5 ± 4.8 0.003 
VE/MVVpeak 60.4 ± 16.9 67.6 ± 17.7 0.132 
SpO2peak,% 97.1 ± 1.5 97.7 ± 0.9 0.106 
O2pulsepeak, ml•min
-1/bpm-1 15.7 ± 2.6 13.0 ± 2.5 0.803 
HRpeak, bpm
-1 151.1 ± 17.7 171.2 ± 12.6 <0.001 
SBPpeak, mmHg 188.3 ± 21.9 173.1 ± 17.9 0.009 
DBPpeak, mmHg 91.3 ± 8.2 85.4 ± 8.2 0.011 
DBP = diastolic blood pressure; fβ = breath frequency; HR = heart rate; MVV = maximum voluntary volume; 
O2pulse = ratio between oxygen uptake and heart rate; PETCO2 = end-tidal carbon dioxide pressure; PETO2 = end-
tidal oxygen pressure; RER = respiratory exchange ratio; SBP = systolic blood pressure; SpO2 = blood oxygen 
saturation with pulse oximetry; VCO2 = carbon dioxide output, VE = minute ventilation; VO2 = oxygen uptake.  
 
Table 3. Discriminant function coefficients 
Variable Coefficient 
ERV, % of predicted 0.372 
PETCO2peak, mmHg -0.376 
SpO2resting % 0.667 
Leg Fatigue, Borg Scale 0.564 
HRpeak, bpm
-1 0.530 
DBPpeak, mmHg -0.543 
ERV = expiratory reserve volume; DBP = diastolic blood pressure; HR = heart rate; PETCO2 = end-tidal carbon 
dioxide pressure; SpO2 = blood oxygen saturation with pulse oximetry. 
